To ensure users receive a high-quality device, CEO Søren Nielsen says Demant has lobbied the FDA through a US-based industry association as it attempts to established the rules for the upcoming over-the-counter hearing aids sales channel.
The hearing aid giant now expects revenue growth of 15-19% measured in local currencies, compared to a previous 17-21%.
The Danish hearing aid manufacturer’s diagnostics business area is a beacon of light among gloomy H1 financial figures, mostly coming from headset firm Epos, says CEO Søren Nielsen.
The preventive migraine treatment, Vyepti, will likely be a key element of the Danish pharmaceutical firm’s upcoming second quarterly report on Wednesday.
Demand for hearing aids on the US market will return in the future, according to Demant CEO Søren Nielsen, who thinks people are postponing the decision to acquire a device due to the challenging economic environment.
Resound Omnia, a new product platform from GN Hearing, is said to provide a 150% improvement in speech understanding compared to older devices.
Last time the hearing aid manufacturer launched a product was during the pandemic. The market now is more open, meaning that there are more opportunities for physical launching events, says company CEO Gitte Aabo.
Although the Danish hearing aid manufacturer just revised its financial expectations for the full year, it hasn’t all been bad for Demant in the second quarter, a Sydbank analyst concludes.
The hearing aid giant’s downgrade could potentially impact its Danish competitors, says a Sydbank analyst.
Hearing aid firm Demant has downgraded its full-year guidance after its revenue for the first six months of 2022 failed to meet analyst expectations. (Updated)
Genmab is recruiting to meet its goals for the future, which is intensifying the CEO role for Jan van de Winkel. Under his reign, the Danish biotech firm has gone from fewer than 200 people to 1,500 now.
Several factors will have hampered growth conditions for the Danish hearing aid manufacturer in recent months, a Jyske Bank analyst points out.
The biotech firm’s migraine drug soared in the latest quarter – even though Pfizer’s acquisition deal has not been finalized.
After releasing a positive report for the second quarter, CEO Jan van de Winkel tells MedWatch how Genmab can beat traditional pharmaceutical companies on sales in the future.
A representative for the Novo Nordisk owner has refused to say whether the company received insider trading information about Convatec from the company’s former chairman, who has been fined for his involvement.
A new dose-sparing technique to extend the US supply of Bavarian Nordic’s monkeypox vaccine has been met with widespread safety concerns, with the vaccine maker’s CEO expressing ”reservations” about the method.
A Sydbank analyst following the Danish biotech firm is very interested in the accelerating sales of cancer drug Darzalex, which Genmab reported after Q2.
After expanding the target group for who gets the monkeypox vaccine last week, Bavarian Nordic’s homeland was in need of more doses.
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Miss anything?
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
Despite the conflict between Russia and Ukraine, the allergy firm has ongoing pediatric trials in both countries. CEO Carsten Hellmann was initially surprised that this was possible in a warzone.
The outcome of a crucial study comparing drug candidate Hexabody-CD3 and Darzalex could have consequences for Genmab and Janssen’s co-development partnership, says CEO Jan van de Winkel.
Medical Director 
Senior Clinical Trial Manager - Black Swans Exist 
QA Manager, QA Commercial Operations, Ascendis Pharma 
Key Account Manager Lead Auditor – Senior Quality Assurance Specialist Lead Automation Engineer ABB Sattline/ABB 800XA, AFRY IT QA Manager Medical Advisor (Metabolism) 
Director Regulatory Affairs 
Antibody Engineering Scientist Principal Laboratory Technologist Medicinal Chemistry 
GMP Compliance Consultant for Eltronic in Ballerup Clinical Project/Trial Manager, Synklino 
Quality coordinator for Aseptic Production, ALK Sales Manager Europa, Ropox Senior Evidence Generation Manager 
Sales Director, Nordic Hospital Solutions, at Mediq Denmark Head of Regulatory Services Denmark Senior Scientist for Analytical Development 
Scientist Radiochemistry 
Global Quality Director (Business Unit Quality Lead) Experienced Biostatistician Senior Toxicologist 
Clinical Trial Manager - Black Swans Exist Senior Electronics Engineer 
